

May 29, 2018



Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 29, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Isaac Ciechanover, M.D., the Company's President and Chief Executive Officer, will participate at two upcoming investor conferences in June:

Jefferies 2018 Global Healthcare Conference

Company Presentation: Tuesday, June 5, 2018 at 11:00 a.m. ET
Grand Hyatt in New York, NY

Goldman Sachs 39th Annual Global Healthcare Conference

Fireside Chat: Tuesday, June 12, 2018 at 1:20 p.m. PT
Terranea Resort in Rancho Palos Verdes, CA

Live audio webcasts of the presentations will be available by visiting the Investors section of the Atara website at www.atarabio.com. Archived replays of the webcasts will be available on the Company's website for 14 days following each presentation.

About Atara Biotherapeutics, Inc.

[Atara Biotherapeutics, Inc. \(@Atarabio\)](http://www.atarabio.com) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara's most advanced T-cell immunotherapy in development, tab-cel™ (tabelecleucel), is being developed for the treatment of patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD), as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC). Atara is also developing off-the-shelf, allogeneic ATA188 and autologous ATA190 T-cell immunotherapies using a complementary targeted antigen recognition technology for specific EBV antigens believed to be important for the potential treatment of multiple sclerosis (MS). Atara's clinical pipeline also includes ATA520 targeting Wilms Tumor 1, or WT1, and ATA230 directed against cytomegalovirus, or CMV. The Company was founded in 2012 and is headquartered in South San Francisco, California.

INVESTOR & MEDIA CONTACTS:

Investors:

John Craighead, Atara Biotherapeutics
650-410-3012
jcraighead@atarabio.com

Steve Klass, Burns McClellan
212-213-0006 x331

sklass@burnsmc.com

Media:

Justin Jackson, Burns McClellan

212-213-0006 x327

jjackson@burnsmc.com

Primary Logo



Source: Atara Biotherapeutics, Inc.